Objective: To assess seizure control and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy to one baseline antiepileptic drug (AED), in adults with partialonset seizures (POS) with or without secondary generalization.
the date, the time, and the type of the seizure episodes (1-simple partial seizure; 2-complex partial seizure; 3-partial seizures with secondary generalization; 4-unclassified seizure; 5-other type of seizure). In addition, the patient recorded the ESL intake on a daily basis.
| Endpoints
The primary endpoint was the retention rate (RR), defined as the proportion of patients on ESL treatment at the end of follow-up, based on the patient diary records.
The secondary endpoints included the proportion of responders (patients with at least 50% reduction in seizure frequency compared to baseline), proportion of seizure-free patients, and the change in frequency for partial seizures with or without secondary generalization.
Seizure frequency at Vinterm and final visit (Vfinal) was standardized for a 4-week period to allow for comparisons with baseline (4 weeks).
The CGI-S is a clinician-rated measure of global psychopathology, which measures severity of mental illness on a 7-point scale, from normal to extremely ill. 13, 14 The CGI-S was evaluated at baseline and at Vfinal. CGI-C is a clinician-reported 7-point scale to measure improvement or worsening of the epilepsy, with lower scores indicating greater improvement (scores range from 1=very much improved to 7=very much worse). 13, 14 The efficacy index is a composite score that reflects the degree of therapeutic effect of ESL treatment, rating it from 1=unchanged to worse to 4=marked, as well as the side effects, classifying them as 1=none to 4=outweighs therapeutic effect. 15 Adverse events occurring during the follow-up period were recorded by the investigator, including the date of occurrence, duration, treatment, outcome, and assessed with regard to causality (not related, unlikely, possible, probable, or definite) and seriousness.
This study was approved by the ethics committee of each participant hospital.
| Statistical analysis
Quantitative variables were summarized as median, minimum, and maximum and qualitative variables as absolute frequency. Nonparametric
Wilcoxon test (W) was used to analyze within-patient paired analysis of CGI-S and seizure frequency between baseline, intermediate, and
final assessment, as normality assumption was rejected.
Bivariate analysis was conducted using baseline independent variables (age, gender, presence of comorbidities, previous AED therapy, CGI-S, and seizure frequency at baseline) and the dependent variables (retention rate, responder rate, and proportion of seizure-free patients). Chi-square or Fisher's exact test was used for categorical variables, and t-test or Mann-Whitney for numerical variables Missing data were not replaced and a valid case approach was assumed, with the exception of the retention rate analysis, in which patients who had no follow-up data available were considered as failures.
All statistical tests were two-tailed considering a significance level of 5% and using 95% confidence intervals (95% CI), when applica- 
| RESULTS

| Characterization of participants
A total of 52 patients (48.1% males) were enrolled. Although two patients had their final follow-up assessment 23 and 39 days after month 9, they were included in the analysis dataset. The study population baseline characteristics are described in Table 1 
| Seizure control
Responder rate was 55.8% (95% CI, 41.0%-70.6%) at Vinterm and 71.1% (95% CI, 56.7%-85.5%) at Vfinal.
Responder rate by concomitant baseline AED is shown in Figure 2 .
Patients on CBZ showed a higher RR at Vfinal (85.7%) compared to patients receiving other AEDs. The responder rate among patients on VPA was 100%.
Overall, the seizure-free rate was 32.6% (95% CI, 18.6%-46.6%) at Vinterm and 39.5% (95% CI, 24.00%-55.04%) at Vfinal ( Figure 3 ). The highest seizure-free rates were found for the secondary generalized seizures (94.7% at Vfinal).
Seizure-free patients had lower frequency of seizures at baseline than non-seizure-free patients (P=0.052). 
T A B L E 1 Study population baseline characteristics
Total (n=52)
Gender, n (%) 
| Adverse events
All 52 patients were eligible for safety analysis (Table 2) . Overall, 23
AEs were reported during the study, of which 19 (82.6%) were possibly, probably, or definitely related to the study treatment. Twelve (23.1%) patients had at least one AE, ten patients (19.2%) had at least one AE related to study treatment, and eight had multiple AEs. Three serious adverse events were reported (pneumonia-sepsis, polyarthralgia, and cutaneous rash). Pneumonia-sepsis was unlikely to be related to the study treatment, whereas polyarthralgia and cutaneous rash were possibly related. Five patients (9.6%) were withdrawn from the study due to AEs (one due to alopecia, burning sensation in eye, and vaginal burning; one due to cutaneous eruption; one due to aggravation of seizures, anxiety, and depressive symptoms; one due to polyarthralgia and cutaneous rash; and one due to generalized erythematopapulous cutaneous eruption).
| CGI-S score at Vf inal and change from baseline
At Vfinal, 36.8% of patients were classified as normal regarding the severity of illness evaluated by CGI-S and 55.3% were borderline or mildly ill. Only about 8% of the patients were moderately or markedly ill. Compared to baseline, 42.1% of the patients reached a less severe disease level, whereas 13.2% attained a more severe level of epilepsy.
In 45% of the patients, CGI-S remained stable.
Although the P-value is in the borderline of significance (P=.066), no statistical differences were found in CGI-S between baseline and Vfinal.
CGI-S score at baseline was found to be statistically associated with the seizure-free rate (P=.011) and RR (P=.024).
| CGI-C and efficacy index scores
According to CGI-C, 73.6% of the patients had their epilepsy "much improved" or "very much improved" at Vfinal. There were no cases where epilepsy was considered worse. In addition, the therapeutic effect of ESL was classified by physicians as "marked" or "moderate" for 42.1% and 36.8% of patients, respectively. No side effects were reported by physicians for 78.9% of patients, and for 18.4%, the side effects "did not significantly interfere with patients' functioning".
| DISCUSSION
The efficacy and safety/tolerability of ESL as adjunctive therapy were previously established in several clinical trials. The primary endpoint of the study was RR, which is of utmost importance in the analysis of long-term AED treatments as it reflects the complex interactions between efficacy and tolerability. 16 This study showed RR of 73.0% at the Vfinal. At 6 months, higher RR was found in a similar non-interventional prospective study (EPOS) 17 (82.2%), in a 1-year retrospective study 18 (80.1%), and in a 2-year retrospective study 16 (82.9%). The lower RR obtained in this study may be due to an underestimation, as a worst scenario was used by classifying those patients that did not perform the final assessment as failures.
We observed a responder rate of 71.1% at Vfinal. The proportion of responders is lower than the one reported in EPOS study, 17 in which 81.8% of patients presented a reduction in seizure frequency of at least 50% at 6 months. These results might be explained by the fact that EPOS population seemed to be less refractory in comparison to our study, as suggested by a shorter mean time since epilepsy diagnosis (12.3±12.1 years in EPOS 19 vs 18.5±14.8 years in this study). On the other hand, the responder rate attained in this study is significantly higher than the ones reported in the 1-year and 2-year retrospective studies 16, 18 at 6 months (57.9% and 25.7%, respectively). Two main reasons might be responsible for these differences. First, the responder rate observed in the ESLADOBA study may be overestimated, as it only considered patients who completed the study (responder rate was calculated not considering the patients who were droppedout from the study, n=14). Second, the patients included in the two Adverse events related to study treatment includes possible, probable and definitely related events. The most frequent adverse events (MedDRA PT) related to study treatment were rash (n=3), toxicity to various agents (n=2), anxiety (n=2), seizure (n=2). The two serious adverse events (MedDRA PT) considered at least possible related to study treatment were arthralgia and rash. MedDRA PT, Medical Dictionary for Regulatory Activities preferred term.
In previous experience with ESL, the incidence of psychiatric AEs (a frequent complaint in patients with epilepsy) was low, which is in accordance with our study. 20 The observational nature of our study could provide an explanation for the considerably lower rates and different profile of AEs, observed in comparison to the phase III trials. Phase III Clinical trials are conducted in a more "controlled" environment, often leading to an overreporting of safety outcomes (somnolence, dizziness, between others), which might be not reported in observational studies. [20] [21] [22] The possible role of patients' age and therapy duration in the developing AEs was not performed and discussed due to the low number of AEs reported. Additionally, 9.6% of the patients discontinued ESL due to AEs, which is lower than the percentages reported in EPOS This study has limitations which advise caution when interpreting the results. First, as it was an observational study, the control for confounders is limited in comparison with the rigid setting of clinical trials. Additionally, visits were not made at fixed time points across patients, and therefore, seizure frequency was calculated on events occurring within different time intervals. Nevertheless, seizure frequency at Vinterm and Vfinal was standardized for a 4-week period to allow for comparisons with baseline frequency. Secondly, seizure frequency and seizure-free rate were collected using patients' diaries potentially leading to less accurate data. Moreover, it only reflects patients who completed the Vinterm and Vfinal (discontinuations were not considered). Finally, due to low numbers, the confidence intervals were considerably wide leading to lack of power to detect statistically significant associations between patients' characteristics and study main endpoints, and limiting the use of multivariable models.
| CONCLUSIONS
Attending clinical practice of ESL showed good retention rates and elicited a significant reduction in seizure frequency in patients with partial-onset seizures not sufficiently controlled with monotherapy.
Our study is in accordance with other observational studies showing favorable tolerability and an efficient seizure control of ESL in adjunctive treatment in this setting. Further research with larger sample sizes is recommended to validate these results.
